The importance of evaluating differences in HES formulations used in hematopoietic progenitor cell cryopreservation.

[1]  E. Davidow,et al.  Clinical Pharmacology and Administration of Fluid, Electrolyte, and Blood Component Solutions , 2017 .

[2]  D. Linch,et al.  Optimisation and quality control of cell processing for autologous stem cell transplantation , 2016, British journal of haematology.

[3]  M. Marconi,et al.  An update on methods for cryopreservation and thawing of hemopoietic stem cells. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[4]  S. Mitra,et al.  Are All Colloids Same? How to Select the Right Colloid? , 2009, Indian journal of anaesthesia.

[5]  S. Heimfeld,et al.  A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch , 2003, Bone Marrow Transplantation.

[6]  K. Schimrigk,et al.  Increased haemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch. , 1997, Arzneimittel-Forschung.

[7]  K. Luo,et al.  Effect of dimethylsulfoxide and hydroxyethyl starch in the preservation of fractionated human marrow cells. , 1994, Cryobiology.

[8]  E. Erbe,et al.  Mechanism of cryoprotection by extracellular polymeric solutes. , 1988, Biophysical journal.

[9]  B. Swanson.  Medical use of dimethyl sulfoxide (DMSO). , 1985, Reviews in clinical & basic pharmacology.

[10]  M. Ashwood‐Smith.  Preservation of Mouse Bone Marrow at −79° C. with Dimethyl Sulphoxide , 1961, Nature.